Defactinib Clinical Trials (2026): 33 Studies for Ovarian Cancer & Low Grade Serous Ovarian Cancer
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
33 Defactinib clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 28 indications (including Ovarian Cancer & Low Grade Serous Ovarian Cancer) and 8,551 total planned enrollment. 1 Phase 3 Defactinib trial and 18 Phase 2 are listed. 13 Defactinib clinical trials are actively recruiting at 71 U.S. sites across 24 states. Most recent activity: NCT06072781 (Feb 2031).
Where to Participate: All Defactinib Trial Sites in the U.S. (71 sites across 24 states)
Every actively recruiting Defactinibtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AZ | HonorHealth | Phoenix85016 | NCT06072781 | Map |
| AR | University of Arkansas | Little Rock72205 | NCT06072781 | Map |
| CA | UCLA Health | Los Angeles90095 | NCT06072781 | Map |
| CA | UC Davis | Sacramento95817 | NCT06072781 | Map |
| CA | University of California, San Francisco | San Francisco94143 | NCT06072781 | Map |
| CT | Yale University | New Haven06520 | NCT06072781 | Map |
| FL | Florida Cancer Specialists - South | Fort Myers33901 | NCT06072781 | Map |
| FL | Mount Sinai | Miami Beach33140 | NCT06072781 | Map |
| FL | AdventHealth | Orlando32804 | NCT05512208 | Map |
| FL | AdventHealth | Orlando32804 | NCT06072781 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT06072781 | Map |
| FL | Florida Cancer Specialists Research East | West Palm Beach33401 | NCT06072781 | Map |
| GA | Emory Saint Joseph's Hospital | Atlanta30342 | NCT06495125 | Map |
| GA | Emory University Hospital/Winship Cancer Institute | Atlanta30322 | NCT06495125 | Map |
| GA | Emory Winship Cancer Institute | Atlanta30322 | NCT06394804 | Map |
| GA | Winship Cancer Institute at Emory University | Atlanta30322 | NCT06072781 | Map |
| IL | NorthShore University HealthSystem | Evanston60201 | NCT06072781 | Map |
| IA | University of Iowa | Iowa City52242 | NCT06194929 | Map |
| LA | Louisiana State University | New Orleans70112 | NCT06072781 | Map |
| LA | Louisiana State University Medical Center New Orleans | New Orleans70112 | NCT05512208 | Map |
| MD | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Baltimore21287 | NCT06072781 | Map |
| MI | Karmanos Cancer Center | Detroit48201 | NCT06072781 | Map |
| MN | Minnesota Oncology Hematology | Minneapolis55404 | NCT06072781 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT06072781 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT07126158 | Map |
| NJ | Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) | Basking Ridge07920 | NCT05787561 | Map |
| NJ | Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) | Basking Ridge07920 | NCT06007924 | Map |
| NJ | Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) | Basking Ridge07920 | NCT06394804 | Map |
| NJ | Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown07748 | NCT05787561 | Map |
| NJ | Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown07748 | NCT06007924 | Map |
| NJ | Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown07748 | NCT06394804 | Map |
| NJ | Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale07645 | NCT05787561 | Map |
| NJ | Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale07645 | NCT06007924 | Map |
| NJ | Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale07645 | NCT06394804 | Map |
| NM | University of New Mexico Comprehensive Cancer Center | Albuquerque87131 | NCT05512208 | Map |
| NY | Roswell Park Cancer Institute | Buffalo14263 | NCT06072781 | Map |
| NY | Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities) | Commack11725 | NCT06007924 | Map |
| NY | Memorial Sloan Kettering Suffolk -Commack (Limited Protocol Activities) | Commack11725 | NCT05787561 | Map |
| NY | Memorial Sloan Kettering Suffolk -Commack (Limited Protocol Activities) | Commack11725 | NCT06394804 | Map |
| NY | Memorial Sloan Kettering Westchester (Limited Protocol Activities) | Harrison10604 | NCT05787561 | Map |
| NY | Memorial Sloan Kettering Westchester (Limited Protocol Activities) | Harrison10604 | NCT06007924 | Map |
| NY | Memorial Sloan Kettering Westchester (Limited Protocol Activities) | Harrison10604 | NCT06394804 | Map |
| NY | Columbia University Irving Medical Center | New York10032 | NCT06487221 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT05787561 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT06072781 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT06394804 | Map |
| NY | Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York10065 | NCT06007924 | Map |
| NY | Memorial Sloan Kettering Nassau (Limited Protocol Activities) | Rockville Centre11553 | NCT06007924 | Map |
| NY | Memorial Sloan Kettering Nassau (Limited Protocol Activities) | Uniondale11553 | NCT05787561 | Map |
| NY | Memorial Sloan Kettering Nassau (Limited Protocol Activities) | Uniondale11553 | NCT06394804 | Map |
| NC | Atrium Health | Charlotte28203 | NCT06072781 | Map |
| OH | Cleveland Clinic Foundation | Cleveland44195 | NCT06072781 | Map |
| OH | Ohio State | Hilliard43026 | NCT06072781 | Map |
| OK | Stephenson Cancer Center | Oklahoma City73117 | NCT05512208 | Map |
| OK | University of Oklahoma Medical Center | Oklahoma City73104 | NCT06072781 | Map |
| OR | Willamette Valley Cancer Institute | Eugene97401 | NCT06072781 | Map |
| OR | Northwest Cancer Specialists | Portland97227 | NCT06072781 | Map |
| PA | Asplundh Cancer Pavilion | Jefferson Health | Philadelphia19090 | NCT06072781 | Map |
| PA | Allegheny Health Network | Pittsburgh15224 | NCT06072781 | Map |
| TX | Texas Oncology Central | Austin78731 | NCT06072781 | Map |
| TX | Texas Oncology-Fort Worth Cancer Center | Fort Worth76104 | NCT06072781 | Map |
| TX | Houston Methodist | Houston77030 | NCT06072781 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT06072781 | Map |
| TX | MD Anderson Cancer Center | Houston77807 | NCT06369259 | Map |
| TX | Texas Oncology | San Antonio78229 | NCT06072781 | Map |
| TX | Texas Oncology | The Woodlands77380 | NCT06072781 | Map |
| TX | Texas Oncology | Tyler75702 | NCT06072781 | Map |
| UT | Intermountain Medical Center | Murray84107 | NCT06072781 | Map |
| UT | Huntsman Cancer Institute | Salt Lake City84112 | NCT06194929 | Map |
| VA | University of Virginia Health System | Charlottesville22908 | NCT06072781 | Map |
| VA | Virginia Cancer Specialists, PC | Gainesville20155 | NCT06072781 | Map |
Defactinib clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | terminated | withdrawn | not yet recruiting | unknown | Total |
|---|---|---|---|---|---|---|---|---|
| Early P1 | 1 | 1 | ||||||
| P1 | 1 | 1 | 4 | 1 | 1 | 8 | ||
| P1/P2 | 2 | 2 | 1 | 5 | ||||
| P2 | 8 | 5 | 3 | 2 | 18 | |||
| P3 | 1 | 1 |
Recruiting Defactinib clinical trials (13)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT06072781 | RAMP 301A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer | P3 | Low Grade Serous Ovarian Cancer | 270 | Mar 2024 |
| NCT06630260 | 5G-RUBY5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours | P1/P2 | Glioblastoma Multiforme (GBM) | 182 | Nov 2024 |
| NCT07318324 | Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer | P1 | Phase IB | 31 | Jun 2026 |
| NCT07126158 | Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma | P2 | Pancreatic Adenocarcinoma | 36 | Apr 2026 |
| NCT06194929 | DETERMINEDefactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma | P1/P2 | Cutaneous Melanoma | 33 | Mar 2024 |
| NCT05512208 | DURAFAKA Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib | P2 | Endometrioid Cancer | 55 | Feb 2023 |
| NCT06495125 | Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer | P2 | Advanced Lung Adenocarcinoma | 50 | Jul 2024 |
| NCT06487221 | Avutometinib and Defactinib in Diffuse Gastric Cancer | P2 | Gastric Cancer | 27 | Oct 2024 |
| NCT06369259 | Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer | P2 | Advanced Colorectal Cancer | 33 | Feb 2025 |
| NCT05636514 | CELESTIAL-MDSCombined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS | P1 | Myelodysplastic Syndromes | 12 | Dec 2022 |
| NCT06007924 | A Study of Avutometinib and Defactinib in People With Thyroid Cancer | P2 | Thyroid Cancer | 30 | Aug 2023 |
| NCT06394804 | CHAMELEONA Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer | P2 | Low-Grade Serous Ovarian Cancer | 20 | Apr 2024 |
| NCT05787561 | VS-6766A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer | P2 | Mesonephric Gynecologic Cancer | 40 | Mar 2023 |
Defactinib clinical trials by indication
Non Small Cell Lung Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05074810 | RAMP203 | P1/P2 | active not recruiting | Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients |
| NCT04620330 | RAMP202 | P2 | completed | A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer |
| NCT01951690 | — | P2 | completed | Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer |
Low Grade Serous Ovarian Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06072781 | RAMP 301 | P3 | recruiting | A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer |
| NCT06682572 | RAMP201J | P2 | active not recruiting | A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients |
Malignant Pleural Mesothelioma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04201145 | — | P1 | withdrawn | Pembrolizumab + Defactinib In Pleural Mesothelioma |
| NCT01870609 | COMMAND | P2 | terminated | Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma |
Advanced Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04439331 | — | P2 | active not recruiting | Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U) |
| NCT02465060 | — | P2 | active not recruiting | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) |
Phase IB (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07318324 | — | P1 | not yet recruiting | Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer |
Pancreatic Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07126158 | — | P2 | recruiting | Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma |
Advanced Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06369259 | — | P2 | recruiting | Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer |
Glioblastoma Multiforme (GBM) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06630260 | 5G-RUBY | P1/P2 | recruiting | 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours |
Gastric Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06487221 | — | P2 | recruiting | Avutometinib and Defactinib in Diffuse Gastric Cancer |
Advanced Lung Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06495125 | — | P2 | recruiting | Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer |
Low-Grade Serous Ovarian Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06394804 | CHAMELEON | P2 | recruiting | A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer |
Cutaneous Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06194929 | DETERMINE | P1/P2 | recruiting | Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma |
Thyroid Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06007924 | — | P2 | recruiting | A Study of Avutometinib and Defactinib in People With Thyroid Cancer |
Glioblastoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05798507 | — | Early P1 | active not recruiting | Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma |
KRAS Activating Mutation (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05669482 | RAMP205 | P1/P2 | active not recruiting | Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer |
Mesonephric Gynecologic Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05787561 | VS-6766 | P2 | recruiting | A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer |
Endometrioid Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05512208 | DURAFAK | P2 | recruiting | A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib |
Myelodysplastic Syndromes (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05636514 | CELESTIAL-MDS | P1 | recruiting | Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS |
Pancreas Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04331041 | — | P2 | active not recruiting | Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma |
Metastatic Uveal Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04720417 | — | P2 | terminated | Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma |
Low Grade Ovarian Serous Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04625270 | RAMP 201 | P2 | active not recruiting | A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation |
Resectable Pancreatic Ductal Adenocarcinoma (PDAC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03727880 | — | P2 | completed | Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma |
NSCLC (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03875820 | FRAME | P1 | active not recruiting | Phase I Trial of Defactinib and VS-6766. |
Carcinoma, Non-small-cell Lung (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02758587 | FAK-PD1 | P1/P2 | unknown | Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1) |
Advanced Solid Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02546531 | — | P1 | completed | Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer |
Healthy Subjects (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02913716 | VS-6063 | P1 | completed | A Phase I, Open-label Study of Absorption, Metabolism, and Excretion of Defactinib (VS-6063) in Healthy Male Subjects |
Non Hematologic Cancers (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01943292 | — | P1 | completed | Phase I Dose Escalation Study of VS-6063 in Japanese Subjects With Non-Hematologic Malignancies |
Ovarian Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01778803 | — | P1 | completed | Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer |
Defactinib pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| RAMP 301 | NCT06072781 | P3 | recruiting | Low Grade Serous Ovarian Cancer | 270 | PMID 39375168 |
| DURAFAK | NCT05512208 | P2 | recruiting | Endometrioid Cancer | 55 | — |
| RAMP201J | NCT06682572 | P2 | active not recruiting | Low Grade Serous Ovarian Cancer | 16 | — |
| CHAMELEON | NCT06394804 | P2 | recruiting | Low-Grade Serous Ovarian Cancer | 20 | — |
| VS-6766 | NCT05787561 | P2 | recruiting | Mesonephric Gynecologic Cancer | 40 | — |
| RAMP 201 | NCT04625270 | P2 | active not recruiting | Low Grade Ovarian Serous Adenocarcinoma | 225 | PMID 38493021 |
| RAMP202 | NCT04620330 | P2 | completed | Non Small Cell Lung Cancer | 90 | PMID 35285277 |
| COMMAND | NCT01870609 | P2 | terminated | Malignant Pleural Mesothelioma | 344 | PMID 30785827 |
Terminated and withdrawn Defactinib trials (3)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT04720417terminatedDefactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma
- NCT04201145withdrawnPembrolizumab + Defactinib In Pleural Mesothelioma
- NCT01870609terminatedPlacebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
All Defactinib trials (33)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06072781 | RAMP 301 | A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer | P3 | recruiting | 270 | Verastem, Inc. | Mar 2024 |
| NCT06630260 | 5G-RUBY | 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours | P1/P2 | recruiting | 182 | Institute of Cancer Research, United Kingdom | Nov 2024 |
| NCT07318324 | Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer | P1 | not yet recruiting | 31 | M.D. Anderson Cancer Center | Jun 2026 | |
| NCT07126158 | Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma | P2 | recruiting | 36 | Washington University School of Medicine | Apr 2026 | |
| NCT06194929 | DETERMINE | Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma | P1/P2 | recruiting | 33 | University of Utah | Mar 2024 |
| NCT05512208 | DURAFAK | A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib | P2 | recruiting | 55 | University of Oklahoma | Feb 2023 |
| NCT06495125 | Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer | P2 | recruiting | 50 | Emory University | Jul 2024 | |
| NCT06487221 | Avutometinib and Defactinib in Diffuse Gastric Cancer | P2 | recruiting | 27 | Ryan H. Moy, MD, PhD | Oct 2024 | |
| NCT06369259 | Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer | P2 | recruiting | 33 | M.D. Anderson Cancer Center | Feb 2025 | |
| NCT05636514 | CELESTIAL-MDS | Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS | P1 | recruiting | 12 | Clinical Hub for Interventional Research (CHOIR) | Dec 2022 |
| NCT05798507 | Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma | Early P1 | active not recruiting | 14 | Emory University | Jul 2023 | |
| NCT06682572 | RAMP201J | A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients | P2 | active not recruiting | 16 | Verastem, Inc. | Oct 2024 |
| NCT05669482 | RAMP205 | Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer | P1/P2 | active not recruiting | 40 | Verastem, Inc. | Mar 2023 |
| NCT06007924 | A Study of Avutometinib and Defactinib in People With Thyroid Cancer | P2 | recruiting | 30 | Memorial Sloan Kettering Cancer Center | Aug 2023 | |
| NCT06394804 | CHAMELEON | A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer | P2 | recruiting | 20 | Memorial Sloan Kettering Cancer Center | Apr 2024 |
| NCT05074810 | RAMP203 | Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients | P1/P2 | active not recruiting | 153 | Verastem, Inc. | Apr 2022 |
| NCT04331041 | Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma | P2 | active not recruiting | 42 | Washington University School of Medicine | Aug 2021 | |
| NCT05787561 | VS-6766 | A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer | P2 | recruiting | 40 | Memorial Sloan Kettering Cancer Center | Mar 2023 |
| NCT04439331 | Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U) | P2 | active not recruiting | 35 | National Cancer Institute (NCI) | Nov 2015 | |
| NCT04625270 | RAMP 201 | A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation | P2 | active not recruiting | 225 | Verastem, Inc. | Dec 2020 |
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | P2 | active not recruiting | 6,452 | National Cancer Institute (NCI) | Aug 2015 | |
| NCT03875820 | FRAME | Phase I Trial of Defactinib and VS-6766. | P1 | active not recruiting | 87 | Institute of Cancer Research, United Kingdom | Dec 2017 |
| NCT03727880 | Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma | P2 | completed | 28 | Lei Zheng | Jun 2019 | |
| NCT04720417 | Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma | P2 | terminated | 13 | Thomas Jefferson University | Jan 2021 | |
| NCT04620330 | RAMP202 | A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer | P2 | completed | 90 | Verastem, Inc. | Dec 2020 |
| NCT04201145 | Pembrolizumab + Defactinib In Pleural Mesothelioma | P1 | withdrawn | 0 | Raphael Bueno, MD | Sep 2020 | |
| NCT02758587 | FAK-PD1 | Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1) | P1/P2 | unknown | 59 | NHS Greater Glasgow and Clyde | Jul 2017 |
| NCT02546531 | Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer | P1 | completed | 43 | Washington University School of Medicine | Feb 2016 | |
| NCT01951690 | Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer | P2 | completed | 55 | Verastem, Inc. | Sep 2013 | |
| NCT01870609 | COMMAND | Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma | P2 | terminated | 344 | Verastem, Inc. | Sep 2013 |
| NCT02913716 | VS-6063 | A Phase I, Open-label Study of Absorption, Metabolism, and Excretion of Defactinib (VS-6063) in Healthy Male Subjects | P1 | completed | 5 | Verastem, Inc. | Aug 2015 |
| NCT01778803 | Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer | P1 | completed | 22 | Verastem, Inc. | Feb 2013 | |
| NCT01943292 | Phase I Dose Escalation Study of VS-6063 in Japanese Subjects With Non-Hematologic Malignancies | P1 | completed | 9 | Verastem, Inc. | Sep 2013 |
Defactinib clinical trials: frequently asked questions
- How many Defactinib clinical trials are there?
- 33 Defactinib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 12 are actively recruiting participants. 7 are marked completed.
- Are Defactinib clinical trials recruiting in 2026?
- Yes — 12 Defactinib trials are actively recruiting in 2026, with 71 U.S. sites across 24 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Defactinib being studied for?
- Defactinib is being studied for Ovarian Cancer, Low Grade Serous Ovarian Cancer, Pancreas Cancer, Pancreatic Cancer, KRAS Activating Mutation and 104 more. The trials are grouped by indication on this page.
- What phase is Defactinib in?
- Defactinib clinical trials span 1 Phase 3, 18 Phase 2, 8 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Defactinib clinical trials?
- The lead sponsor across the most Defactinib trials is Verastem, Inc., with 14 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Defactinibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: